Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 11;127:106–115. doi: 10.1016/j.ijid.2022.12.009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

SARS-CoV-2-specific antibody responses. (a) No significant difference in antispike and antinucleocapsid antibody titers between HIV- and HIV+ groups at baseline. The antibody titers were high in both groups. The median dilutions for both antispike and antinucleocapsid antibodies in both groups was 1: 1280. (b) At follow-up, the median antibody titer against spike (1: 1280) was higher than that against nucleocapsid protein (1: 640) in both groups. There were no significant differences in antispike antibody titers between the two groups at follow-up, while the antinucleocapsid antibody titer was significantly higher in the HIV+ group as indicated by the distribution of more individuals with higher titers compared to the HIV- group. (c) There was a significant decrease in antispike antibody titers in the HIV- group at follow-up, while no significant change between baseline and follow-up titers was observed in the HIV+ group. (d) There was a statistically significant decrease in antinucleocapsid antibody titers after 8 weeks of follow-up in both the HIV- and HIV+ groups. The titer on Y-axis indicate the number of dilutions.